Show simple item record

dc.contributor.authorFan, Yuchen
dc.contributor.authorKuai, Rui
dc.contributor.authorXu, Yao
dc.contributor.authorOchyl, Lukasz J.
dc.contributor.authorMoon, James J.
dc.contributor.authorIrvine, Darrell J
dc.date.accessioned2019-03-01T17:21:18Z
dc.date.available2019-03-01T17:21:18Z
dc.date.issued2017-12
dc.date.submitted2017-07
dc.identifier.issn1530-6984
dc.identifier.issn1530-6992
dc.identifier.urihttp://hdl.handle.net/1721.1/120592
dc.description.abstractDespite their potential, conventional whole-cell cancer vaccines prepared by freeze-thawing or irradiation have shown limited therapeutic efficacy in clinical trials. Recent studies have indicated that cancer cells treated with certain chemotherapeutics, such as mitoxantrone, can undergo immunogenic cell death (ICD) and initiate antitumor immune responses. However, it remains unclear how to exploit ICD for cancer immunotherapy. Here, we present a new material-based strategy for converting immunogenically dying tumor cells into a powerful platform for cancer vaccination and demonstrate their therapeutic potential in murine models of melanoma and colon carcinoma. We have generated immunogenically dying tumor cells surface-modified with adjuvant-loaded nanoparticles. Dying tumor cells laden with adjuvant nanodepots efficiently promote activation and antigen cross-presentation by dendritic cells in vitro and elicit robust antigen-specific CD8α+ T-cells in vivo. Furthermore, whole tumor-cell vaccination combined with immune checkpoint blockade leads to complete tumor regression in 78% of CT26 tumor-bearing mice and establishes long-term immunity against tumor recurrence. Our strategy presented here may open new doors to "personalized" cancer immunotherapy tailored to individual patient's tumor cells. Keywords: cancer immunotherapy; cancer vaccine; Cell engineering; innunogenic cell death; nanoparticleen_US
dc.publisherAmerican Chemical Society (ACS)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1021/ACS.NANOLETT.7B03218en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcePMCen_US
dc.titleImmunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapyen_US
dc.typeArticleen_US
dc.identifier.citationFan, Yuchen et al. “Immunogenic Cell Death Amplified by Co-Localized Adjuvant Delivery for Cancer Immunotherapy.” Nano Letters 17, 12 (November 22, 2017): 7387–7393 © 2017 American Chemical Societyen_US
dc.contributor.departmentDavid H. Koch Institute for Integrative Cancer Research at MITen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Materials Science and Engineeringen_US
dc.contributor.mitauthorIrvine, Darrell J
dc.relation.journalNano Lettersen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2019-02-08T12:13:53Z
dspace.orderedauthorsFan, Yuchen; Kuai, Rui; Xu, Yao; Ochyl, Lukasz J.; Irvine, Darrell J.; Moon, James J.en_US
dspace.embargo.termsNen_US
mit.licensePUBLISHER_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record